An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2018
Price : $35 *
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Basal cell cancer
- Focus Biomarker; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 17 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.